Dr Reddy's Laboratories (DRL) has completed the acquisition of GlaxoSmithKline's US oral penicillin facility and product portfolio pursuant to the agreement signed and announced by the companies on November 23, 2010.
As a result of the acquisition, DRL assumes the ownership of the penicillin manufacturing site in Bristol, Tennessee, United States, and rights for the Augmentin and Amoxil brands in the United States. GSK will retain the existing rights for these brands outside the United Sates. Further financial terms and conditions of the transaction are not being disclosed.